A DNA robotic switch with regulated autonomous display of cytotoxic ligand nanopatterns.

Journal: Nature nanotechnology
Published Date:

Abstract

The clustering of death receptors (DRs) at the membrane leads to apoptosis. With the goal of treating tumours, multivalent molecular tools that initiate this mechanism have been developed. However, DRs are also ubiquitously expressed in healthy tissue. Here we present a stimuli-responsive robotic switch nanodevice that can autonomously and selectively turn on the display of cytotoxic ligand patterns in tumour microenvironments. We demonstrate a switchable DNA origami that normally hides six ligands but displays them as a hexagonal pattern 10 nm in diameter once under higher acidity. This can effectively cluster DRs and trigger apoptosis of human breast cancer cells at pH 6.5 while remaining inert at pH 7.4. When administered to mice bearing human breast cancer xenografts, this nanodevice decreased tumour growth by up to 70%. The data demonstrate the feasibility and opportunities for developing ligand pattern switches as a path for targeted treatment.

Authors

  • Yang Wang
    Department of General Surgery The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology Kunming China.
  • Igor Baars
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Ieva Berzina
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Iris Rocamonde-Lago
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Boxuan Shen
    Biohybrid Materials, Department of Bioproducts and Biosystems, Aalto University, 00076 Aalto, Finland.
  • Yunshi Yang
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Marco Lolaico
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Janine Waldvogel
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Ioanna Smyrlaki
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Keying Zhu
    Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Robert A Harris
    Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Björn Högberg
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. bjorn.hogberg@ki.se.